Pradaxa Attorneys at Morgan & Morgan Alert Patients to New FDA Announcement on Bleeding Risk

The attorneys at Morgan and Morgan are reporting that the FDA announced that it did not find a higher risk of bleeding in Pradaxa users when compared to those taking warfarin. Their announcement, however, has sparked criticism that it failed to address the drug’s lack of an antidote. Tampa, FL (PRWEB) December 03, 2012 Approximately one year after announcing that it would be evaluating post-marketing reports of bleeding in Pradaxa users, the FDA has reported that it did not find a higher risk of bleeding in Pradaxa users when compared to those taking warfarin, Morgan and Morgan reports.
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories